Replies to post #392340 on Amarin Corp Plc (AMRN)

[ggwpq]

Yeah, right!

[Whalatane]

SGLT’s don’t reduce risk of revascularisation ( when stents occlude reducing blood flow )

Revascularisation costs up to $40,000 per procedure in the US

This will be a key data pt I’ll be looking for in the RESPECT-EPA data
Chk R-IT REVASCULARISATION data
I want R-E to confirm that risk reduction

Above from memory… I think I linked the above info previously

Kiwi

[Whalatane]

Ralphey… you’re referring to primary prevention aren’t U ?

Vascepa is largely a secondary prevention drug . R-IT is 70 % secondary prevention.
MITIGATE and RESPECT-EPA is all secondary prevention data

Kiwi